HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effectiveness of intravenous ilomedin infusion and smoking cessation in the treatment of acutely symptomatic Buerger disease.

Abstract
We assessed the effectiveness of iloprost treatment in the management of symptomatic Buerger disease (BD) and assessed smoking cessation compliance, based on a single-center experience. Thirteen patients with BD were treated with sessions of intravenous (IV) Ilomedin infusion. At 1-year follow-up, pain status alteration, number of analgesics required, ankle-brachial index (ABI) change, compliance with supervised smoking cessation, and amputation-free rate were recorded. The pain status improved considerably according to a visual analog scale, the number of analgesics required was significantly reduced, and all patients improved their pain-free walking distance, the ABI, and their self-reported quality of life. Only 2 patients required minor amputations. Combination of IV Ilomedin infusion, supervised smoking cessation, and a specific follow-up protocol may lead to improvement in pain-free walking distance, pain status, quality of life, and substantial reduction in amputation risk.
AuthorsKostas Spanos, Evangelia Georgiou, Vassileios Saleptsis, Athanasios Athanasoulas, Lazaros Sakkas, Athanasios D Giannoukas
JournalAngiology (Angiology) Vol. 66 Issue 2 Pg. 114-7 (Feb 2015) ISSN: 1940-1574 [Electronic] United States
PMID24366824 (Publication Type: Journal Article)
Copyright© The Author(s) 2013.
Chemical References
  • Analgesics
  • Platelet Aggregation Inhibitors
  • Vasodilator Agents
  • Iloprost
Topics
  • Amputation, Surgical
  • Analgesics (therapeutic use)
  • Ankle Brachial Index
  • Combined Modality Therapy
  • Disease-Free Survival
  • Exercise Tolerance (drug effects)
  • Female
  • Greece
  • Humans
  • Iloprost (administration & dosage)
  • Infusions, Intravenous
  • Limb Salvage
  • Male
  • Middle Aged
  • Pain Measurement
  • Patient Compliance
  • Platelet Aggregation Inhibitors (administration & dosage)
  • Predictive Value of Tests
  • Quality of Life
  • Recovery of Function
  • Risk Factors
  • Smoking (adverse effects)
  • Smoking Cessation
  • Smoking Prevention
  • Thromboangiitis Obliterans (diagnosis, drug therapy, etiology, physiopathology)
  • Time Factors
  • Treatment Outcome
  • Vasodilator Agents (administration & dosage)
  • Walking

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: